Hormonal
Combining Endoscopic Gastric Remodeling (EGR) with a GLP-1 Receptor Agonist (GLP-1RA) initiated within 6 months of the procedure yields significantly greater weight loss (23.7% TWL) than EGR monotherapy or sequential therapy.
If you are considering Endoscopic Gastric Remodeling (EGR), ask about starting a GLP-1RA (like semaglutide or liraglutide) within 6 months of the procedure. This specific combination yields significantly better weight loss (approx. 24%) than either treatment alone. Avoid taking other types of weight loss medications for more than 6 months before the procedure, as this is associated with poorer outcomes.
At 12 months, patients who received EGR + GLP-1RA combination therapy achieved the greatest weight loss (23.7 ±4.6% TWL)... The response rate was 100% for EGR + GLP-1RA combination therapy... Combining AOM with EGR appears to result in greater weight loss compared with other strategies, with GLP-1RA as the preferred agent and optimal initiation of both therapies occurring within 6 months of each other.
Why this rating
Single-center retrospective review; potential selection bias (rescue therapy use); however, large sample size (n=208) and statistical significance support the finding.
Source
Efficacy of anti-obesity medication (AOM) and endoscopic gastric remodeling (EGR): Analysis of combination therapy with optimal timing and agents
Pichamol Jirapinyo et al. · Endoscopy International Open · 2024
DOI 10.1055/a-2463-9784
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →